SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013
- 832 Downloads
Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.
KeywordsHead and neck cancer Induction chemotherapy TPF Cetuximab EXTREME ERBITAX
Conflict of interest
The authors declare that they have no conflict of interest relating to the publication of this manuscript.
- 1.Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality in Europe: estimates for 40 countries in 2012. Eur J Cancer (online version). 2013. doi: 10.1016/j.ejca.2012.12.027.
- 2.TNM Classification. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar
- 5.Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer. Lancet. 2000;355:949–55.PubMedGoogle Scholar
- 7.Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.PubMedCrossRefGoogle Scholar
- 10.Lefebvre JL, And KK. Larynx preservation clinical trial design: key issues and recommendations. A consensus panel summary. Int J Radiation Oncol Biol Phys. 2009;73:1293–303.Google Scholar
- 11.VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Departament of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685–90.Google Scholar
- 14.Pointreau Y, Garuad P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer. 2009;101:498–506.Google Scholar
- 15.Bonner JA, Harari M, Giralt J, Baselga J, Shin D, Cohen R et al. Improved preservation of larynx with the addition of cetuximab to radiotherapy for cancers of the larynx and hypopharynx. J Clin Oncol. 2005;23(16S):5533.Google Scholar
- 17.Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636–45.PubMedCrossRefGoogle Scholar
- 18.Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.Google Scholar
- 19.Hitt R, Irigoyen A, Cortes Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.Google Scholar